Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic mice
Our findings establish TgRANKL mice as a unique osteoporotic model for investigating the mechanisms driving denosumab rebound and testing sequential antiresorptive strategies.
Authors
- Vasileios Ntafis (ORCID: https://orcid.org/0000-0003-1271-1187)
- Athanasios D. Anastasilakis (ORCID: https://orcid.org/0000-0002-9624-6296)
- Vagelis Rinotas (ORCID: https://orcid.org/0000-0002-2390-3136)
- Melina Dragolia
- Eleftheria-Dimitra Ntouskou
- Eleni Douni (ORCID: https://orcid.org/0000-0003-0004-5121)
- Maria P. Yavropoulou (ORCID: https://orcid.org/0000-0002-6501-3692)
- Polyzois Makras
Institutions
- Agricultural University of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- Military Hospital (PK)
- Hellenic Air Force (GR)
- Alexander Fleming Biomedical Sciences Research Center (GR)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-02-26
- DOI
- https://doi.org/10.3389/fendo.2026.1783656
- Primary Topic
- Bone Metabolism and Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00